# Changes in human tear metabolome following topical 0.05% cyclosporine A on primary Sjögren’s syndrome

## TL;DR

This study shows how tear chemistry changes in dry eye patients with Sjögren’s syndrome after using cyclosporine A eye drops.

## Contribution

The study identifies specific metabolite changes in tears linked to cyclosporine A treatment in Sjögren’s syndrome-related dry eye.

## Key findings

- 0.05% cyclosporine A improved clinical parameters like tear breakup time and conjunctival staining in patients.
- 402 metabolites were identified, with 64 showing differential expression after treatment.
- Metabolites related to phenylalanine, tyrosine, and tryptophan biosynthesis were enriched following treatment.

## Abstract

This study aimed to investigate changes in the tear metabolome and the therapeutic impact of 0.05% cyclosporine A (CsA) eye drops in patients with dry eye disease (DED) linked to primary Sjögren’s syndrome (pSS).

Fifteen patients with pSS-related DED were treated with topical 0.05% CsA for 3 months. Ocular examinations were performed, and tear samples were collected at baseline (T0) and 3 months post-treatment (T1). Differentially expressed metabolites were detected and correlated with clinical parameters.

Topical 0.05% CsA treatment significantly improved the Ocular Surface Disease Index score, lid margin vascularity, conjunctival staining, tear breakup time (TBUT), and lid wiper epitheliopathy (LWE) in DED patients (all p < 0.05). A total of 402 metabolites were identified in pSS patients’ tear fluid, with 64 showing differential expression. Pathway analysis identified significant enrichment in the biosynthesis pathways of phenylalanine, tyrosine, and tryptophan. Additionally, certain metabolites (e.g., lipids and anti-inflammatory molecules) correlated positively or negatively with clinical parameters such as TBUT, LWE, and conjunctival staining.

This study underscores significant alterations in tear metabolites at the ocular surface in pSS patients receiving 0.05% topical CsA, offering important insights for managing pSS-related DED clinically.